FGFR1-3 Inhibitor Significantly Increased Growth Rate in Patients with Achondroplasia

A new Phase III study in children with achondroplasia, a common genetic growth disorder, has shown that an innovative treatment yields promising…

This next-generation drug, administered once daily and called an FGFR1-3 tyrosine kinase inhibitor, has provided significant increases in the height of the children participating in the trial. This…